LipoScience Inc, Raleigh, NC, reports data from two studies presented at the Annual Scientific Session of the American College of Cardiology highlights the importance of low density lipoprotein particle (LDL-P) measurements in identifying cardiovascular disease risk for patients.
Previous studies have indicated that many patients with relatively normal levels of low density lipoprotein cholesterol (LDL-C) have increased LDL-P, illustrating discordance between the two measures of LDL. The medical community is increasingly aware of the critical role utilizing LDL-P as measured by nuclear magnetic resonance (NMR) spectroscopy to help manage a patient¹s cardiovascular disease risk.
This data further validates the need for increased awareness of LDL-P as an indicator of cardiovascular disease, and the value of NMR as a differentiated platform technology, according to the company.
- Pamela Morris, MD, FACC, of the Medical University of South Carolina, presented data from the study “Discordance in Low-Density Lipoprotein Particle Number (LDL-P) and Apolipoprotein B (Apo B) Level,” highlighting the relationship between these two biomarkers in assessing cardiovascular risk. The study examined the Apo B and LDL-P values of 1,196 subjects. Ultimately, it was found that a considerable percentage of patients had much higher LDL-P levels despite attaining normal levels of Apo B.
- Another presentation, “NMR-Based Lipoprotein Particle Profiling Identifies Novel Signatures for Cardiovascular Disease,” explored the associations of LDL-P with cross sectional coronary artery disease (CAD) and CAD severity, and the potential as a predictor of incident cardiovascular events. The study analyzed plasma from 1,736 patients who were enrolled in the CATHGEN biorepository of patients undergoing cardiac catheterization at Duke University Medical Center. The study found novel lipoprotein signatures that independently discriminate the presence and extent of CAD and predict incident mortality and myocardial infarction.
[Source: Liposcience]